Published 6 days ago • Updated 4 days ago

Semaglutide Shows Major Benefits in Peripheral Arterial Disease: STRIDE

Summary by Medscape

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a practice-changing trial, according to experts. Medscape Medical News

7 Articles

All

Left

Center

Right

Clinical Trials Arena

ACC 25: semaglutide improves function in PAD patients with T2D in STRIDE study

Novo Nordisk announced results of the Phase IIIb STRIDE trial of semaglutide’s impact on walking capacity in people with PAD and T2D.The post ACC 25: semaglutide improves function in PAD patients with T2D in STRIDE study appeared first on Clinical Trials Arena.

4 days ago

Read Full Article

Pharmaphorum

ACC25: Ozempic shows its value in PAD

Novo Nordisk's Ozempic has been shown to improve walking distance in people with diabetes and peripheral artery disease in the STRIDE trial.

4 days ago

Read Full Article

ScienceDirect

Glucagon-like peptide 1 aggregates into low-molecular-weight oligomers off-pathway to fibrillation

The physical stability of peptide-based drugs is of great interest to the pharmaceutical industry. Glucagon-like peptide 1 (GLP-1) is a 31-amino acid …

5 days ago·Amsterdam, Netherlands

Read Full Article

ajmc.com

Semaglutide Demonstrates Enhanced Walking Capacity in ACC.25 STRIDE Data

STRIDE investigator Marc Bonaca, MD, MPH, University of Colorado School of Medicine, highlights how the data could provide insight into peripheral artery disease and type 2 diabetes treatment options.

5 days ago

Read Full Article

Anti-Aging, Acupuncture and Health News

Reposted by

Dataemia

Semaglutide Shows Major Benefits in PAD: STRIDE

Semaglutide, a GLP-1 agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE trial, the drug significantly improved walking distance, symptoms like pain, and quality of life in patients with symptomatic PAD and type 2 diabetes. It was also associated with a reduction in disease progression and […] The post Semaglutide Shows Major Benefits in PAD: STRIDE first appeared on Ne…

5 days ago

Read Full Article

Medscape

Semaglutide Shows Major Benefits in Peripheral Arterial Disease: STRIDE

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a practice-changing trial, according to experts. Medscape Medical News

6 days ago·United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year